An observational study in Extracorporeal Membrane Oxygenation Complication and Outcome, Fatal, sponsored by Goethe University. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-29.
Sponsored by Goethe University · Observational
In the context of the coronavirus (COVID-19) pandemic, healthcare systems worldwide faced an unprecedented shortage of severe ARDS. Critically affected patients were treated with veno-venous extracorporeal membrane oxygenation (VV-ECMO) for complete respiratory failure early in the pandemic. Due to a shortage of resources in the sense of terminal equipment and adequately trained personnel with appropriate expertise in many countries and regions, a strict selection of suitable patients was made. Repeatedly, it was observed that patients under VV-ECMO also needed several weeks to recover sufficiently to generate device sufficient gas exchange. Due to the scarcity of VV-ECMO resources outside of the pandemic, the question arose whether a prolonged therapy still holds a sufficient prospect of success and what the course of treatment of such patients would be like.
1,881 studies on the registry are indexed under Critical Illness; 462 are open to participants now.
This study's enrollment of 100 is below the median of 130 across 867 observational studies indexed under Critical Illness.
Browse Critical Illness studies →Goethe University is the lead sponsor of 97 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Critically affected patients treated with veno-venous extracorporeal membrane oxygenation (VV-ECMO). Based on severe acute respiratory distress syndrome (ARDS) and prolonged therapy for more than 2 weeks.
veno-venous extracorporeal membrane oxygenation
Exclusion Criteria:
veno-arterial extracorporeal membrane oxygenation
Critically affected patients treated with veno-venous extracorporeal membrane oxygenation (VV-ECMO). Based on severe acute respiratory distress syndrome (ARDS) and prolonged therapy for more than 2 weeks.
Other: Outcome
Mortality rate of prolonged therapy.
Mortality
Mortality rate under ongoing veno-venous extracorporeal membrane oxygenation over time
Time frame: During intensive care treatment (Usually within 25 weeks)
Major bleeding
Number of patients with critical bleeding events during therapy, needing red blood cell transfusion
Time frame: During intensive care treatment (Usually within 25 weeks)
critical device error
Number of patients with a critical device errors of the veno-venous extracorporeal membrane oxygenation device.
Time frame: During intensive care treatment (Usually within 25 weeks)
Plan to share: No — Sharing patient data is not possible due to national and local legal restrictions.
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Goethe University